Evaluation of compliance with the 2017 Canadian Paediatric Society Position Statement for the management of newborns at risk for early-onset sepsis: A retrospective cohort study

N6-methyladenosine (m6A) methyltransferase METTL3 regulates sepsis-induced myocardial injury through IGF2BP1/HDAC4 dependent manner

Recent studies have identified that N⁶-methyladenosine (m⁶A) extensively participates in the myocardial injury pathophysiological process. However, the role of m⁶A on sepsis-induced myocardial injury is still unclear. Here, we investigated the functions and mechanism of m⁶A methyltransferase METTL3 for septic myocardial injury. Results illustrated that the m⁶A modification level and METTL3 up-regulated in the lipopolysaccharide (LPS)-induced cardiomyocytes (H9C2 cells). Methylated RNA immunoprecipitation sequencing (MeRIP-Seq) revealed the m⁶A profile of the septic myocardial injury cellular model. Functionally, METTL3 knockdown repressed the inflammatory damage of cardiomyocytes induced by LPS. Mechanistically, we found that HDAC4 had remarkable m⁶A modification sites on its 3'-UTR genome, acting as the downstream target of METTL3. Besides, m⁶A reader IGF2BP1 recognized the m⁶A modification sites on HDAC4 mRNA and enhanced its RNA stability. In conclusion, the findings illustrated a role of METTL3/IGF2BP1/m⁶A/HDAC4 axis on sepsis-induced myocardial injury, which might provide novel therapeutic strategy for septic myocardial injury.